MA55301A - Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation - Google Patents
Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisationInfo
- Publication number
- MA55301A MA55301A MA055301A MA55301A MA55301A MA 55301 A MA55301 A MA 55301A MA 055301 A MA055301 A MA 055301A MA 55301 A MA55301 A MA 55301A MA 55301 A MA55301 A MA 55301A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- protein tyrosine
- tyrosine phosphatase
- phosphatase inhibitors
- inhibitors
- Prior art date
Links
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818447P | 2019-03-14 | 2019-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55301A true MA55301A (fr) | 2022-01-19 |
Family
ID=70190226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055301A MA55301A (fr) | 2019-03-14 | 2020-03-13 | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10851073B2 (fr) |
| EP (1) | EP3938038A1 (fr) |
| JP (3) | JP7204005B2 (fr) |
| KR (2) | KR102533599B1 (fr) |
| CN (2) | CN114025844B (fr) |
| AR (1) | AR118374A1 (fr) |
| BR (1) | BR112021017430A2 (fr) |
| CA (1) | CA3131894A1 (fr) |
| CL (2) | CL2021002382A1 (fr) |
| CO (1) | CO2021013524A2 (fr) |
| CR (1) | CR20210516A (fr) |
| DO (1) | DOP2021000188A (fr) |
| EC (1) | ECSP21075909A (fr) |
| IL (1) | IL286373B1 (fr) |
| MA (1) | MA55301A (fr) |
| MX (2) | MX2021010544A (fr) |
| MY (1) | MY209419A (fr) |
| PE (1) | PE20212154A1 (fr) |
| PH (1) | PH12021552194A1 (fr) |
| SG (1) | SG11202109067PA (fr) |
| TW (2) | TWI849082B (fr) |
| UY (1) | UY38613A (fr) |
| WO (1) | WO2020186199A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102533599B1 (ko) * | 2019-03-14 | 2023-05-17 | 칼리코 라이프 사이언시스 엘엘씨 | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 |
| WO2021127499A1 (fr) * | 2019-12-18 | 2021-06-24 | Calico Life Sciences Llc | Inhibiteurs de protéine tyrosine phosphatase et leurs méthodes d'utilisation |
| MX2023002953A (es) * | 2020-09-11 | 2023-06-01 | Calico Life Sciences Llc | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. |
| IL305072A (en) * | 2021-02-12 | 2023-10-01 | Recovery Therapeutics Inc | Compounds, compositions, and methods for modulating fgf activity |
| AU2022234402A1 (en) * | 2021-03-11 | 2023-09-28 | Kumquat Biosciences Inc. | Heterocycles and uses thereof |
| WO2022261145A1 (fr) * | 2021-06-10 | 2022-12-15 | Ness Therapeutics, Inc. | Composés ayant un 1,1-dioxyde de 5-(2-fluoro-6-hydroxyphényl)-1,2,5-thiadiazolidin-3-one utiles comme inhibiteurs d'enzymes protéine kinase phosphatase |
| CA3236854A1 (fr) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Inhibiteurs de proteine tyrosine phosphatase et leurs procedes d'utilisation |
| CN118556055A (zh) * | 2021-11-11 | 2024-08-27 | 卡里科生命科学有限责任公司 | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 |
| EP4472958A1 (fr) * | 2022-02-02 | 2024-12-11 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| JP2025505994A (ja) * | 2022-02-02 | 2025-03-05 | ネリオ セラピューティクス，インク． | プロテインチロシンホスファターゼ阻害剤およびその使用 |
| WO2023150535A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| JP2025510741A (ja) * | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| EP4587436A1 (fr) * | 2022-09-13 | 2025-07-23 | Kumquat Biosciences Inc. | N-hétérocycles benzo-fusionnés et leurs utilisations |
| WO2024067802A1 (fr) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | Inhibiteur de protéine tyrosine phosphatase, son procédé de préparation et son utilisation pharmaceutique |
| WO2024141015A1 (fr) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| WO2025011570A1 (fr) * | 2023-07-11 | 2025-01-16 | 深圳众格生物科技有限公司 | Inhibiteur de protéine tyrosine phosphatase, composition le comprenant et son utilisation médicale |
| AR133249A1 (es) | 2023-07-14 | 2025-09-10 | Univ Leuven Kath | Nuevos compuestos |
| WO2025026158A1 (fr) * | 2023-07-28 | 2025-02-06 | 杭州中美华东制药有限公司 | Composés ayant des effets inhibiteurs de ptpn2 et leur utilisation |
| TW202519218A (zh) * | 2023-08-02 | 2025-05-16 | 美商耐瑞歐醫療公司 | 蛋白質酪胺酸磷酸酶抑制劑之組合 |
| WO2025055985A1 (fr) * | 2023-09-15 | 2025-03-20 | 深圳众格生物科技有限公司 | Inhibiteur de protéine tyrosine phosphatase, composition et utilisation médicale |
| CN120004876A (zh) * | 2023-11-16 | 2025-05-16 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| WO2025136841A1 (fr) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Dérivés d'isoquinoléine substitués et leurs procédés d'utilisation |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US7696231B2 (en) | 2001-10-30 | 2010-04-13 | Laboratoires Serono Sa | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| JP2009532379A (ja) * | 2006-03-31 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | ＰＴＰａｓｅのチアジアゾリジノン阻害剤 |
| US20100160228A1 (en) | 2007-05-23 | 2010-06-24 | Valtion Teknillinen Tutkimuskeskus | Method for inhibiting or stimulating angiogenesis in an individual |
| AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| WO2010008852A2 (fr) | 2008-06-23 | 2010-01-21 | Taiga Biotechnologies, Inc. | Procédés de traitement et procédés de diagnostic d’un trouble immunoprolifératif |
| WO2010118241A2 (fr) | 2009-04-08 | 2010-10-14 | Indiana University Research & Technology Corporation | Inhibiteurs des protéine-tyrosine phosphatases |
| WO2011057331A1 (fr) | 2009-11-11 | 2011-05-19 | Monash University | Procédé de traitement de l'obésité |
| EP2531616A4 (fr) | 2010-02-03 | 2013-07-10 | Univ Monash | Dosage de diagnostic et de pronostic pour le cancer du sein |
| HK1211293A1 (en) * | 2012-11-02 | 2016-05-20 | 辉瑞公司 | Bruton's tyrosine kinase inhibitors |
| JP2017513812A (ja) | 2014-02-28 | 2017-06-01 | ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ | 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤 |
| JP2017524348A (ja) | 2014-06-10 | 2017-08-31 | モナッシュ ユニバーシティ | 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法 |
| JP6507234B2 (ja) * | 2014-10-02 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
| WO2017078499A2 (fr) | 2015-11-06 | 2017-05-11 | 경북대학교 산학협력단 | Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase |
| KR101826690B1 (ko) | 2015-11-06 | 2018-03-22 | 경북대학교 산학협력단 | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 |
| WO2018148378A1 (fr) | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulation de biomarqueurs pour accroître l'immunité antitumorale et améliorer l'efficacité d'une immunothérapie anticancéreuse |
| US11273166B2 (en) | 2017-06-13 | 2022-03-15 | Monash University | Methods and compositions for the treatment of obesity |
| CA3073755A1 (fr) | 2017-08-24 | 2019-02-28 | The Royal Institution For The Advancement Of Learning/Mcgill Universit | Amelioration de lymphocytes t cd8+ pour une therapie cellulaire adoptive par inhibition de ptpn1 (ptp1b) et ptpn2 (tc-ptp)) |
| PE20210372A1 (es) | 2018-06-21 | 2021-02-26 | Abbvie Inc | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
| KR102533599B1 (ko) * | 2019-03-14 | 2023-05-17 | 칼리코 라이프 사이언시스 엘엘씨 | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 |
-
2020
- 2020-03-13 KR KR1020217032888A patent/KR102533599B1/ko active Active
- 2020-03-13 CA CA3131894A patent/CA3131894A1/fr active Pending
- 2020-03-13 CN CN202080035755.9A patent/CN114025844B/zh active Active
- 2020-03-13 JP JP2021555178A patent/JP7204005B2/ja active Active
- 2020-03-13 PE PE2021001510A patent/PE20212154A1/es unknown
- 2020-03-13 TW TW109108506A patent/TWI849082B/zh active
- 2020-03-13 MX MX2021010544A patent/MX2021010544A/es unknown
- 2020-03-13 KR KR1020237016132A patent/KR20230074822A/ko not_active Ceased
- 2020-03-13 MY MYPI2021004954A patent/MY209419A/en unknown
- 2020-03-13 BR BR112021017430A patent/BR112021017430A2/pt unknown
- 2020-03-13 PH PH1/2021/552194A patent/PH12021552194A1/en unknown
- 2020-03-13 SG SG11202109067PA patent/SG11202109067PA/en unknown
- 2020-03-13 CN CN202210783687.5A patent/CN116332873A/zh active Pending
- 2020-03-13 CR CR20210516A patent/CR20210516A/es unknown
- 2020-03-13 MA MA055301A patent/MA55301A/fr unknown
- 2020-03-13 TW TW113128010A patent/TW202519515A/zh unknown
- 2020-03-13 EP EP20717505.0A patent/EP3938038A1/fr active Pending
- 2020-03-13 WO PCT/US2020/022717 patent/WO2020186199A1/fr not_active Ceased
- 2020-03-13 MX MX2024010859A patent/MX2024010859A/es unknown
- 2020-03-16 UY UY0001038613A patent/UY38613A/es unknown
- 2020-03-16 AR ARP200100729A patent/AR118374A1/es unknown
- 2020-06-04 US US16/892,786 patent/US10851073B2/en active Active
-
2021
- 2021-09-13 DO DO2021000188A patent/DOP2021000188A/es unknown
- 2021-09-13 CL CL2021002382A patent/CL2021002382A1/es unknown
- 2021-09-13 IL IL286373A patent/IL286373B1/en unknown
- 2021-10-11 CO CONC2021/0013524A patent/CO2021013524A2/es unknown
- 2021-10-13 EC ECSENADI202175909A patent/ECSP21075909A/es unknown
-
2022
- 2022-12-27 JP JP2022209142A patent/JP7617890B2/ja active Active
-
2024
- 2024-06-11 CL CL2024001723A patent/CL2024001723A1/es unknown
-
2025
- 2025-01-07 JP JP2025002163A patent/JP2025061064A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| EP3911640A4 (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| EP3962481A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| MA52091A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| EP3846808A4 (fr) | Inhibiteurs de papd5 et leurs procédés d'utilisation | |
| EP3765006A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
| EP3935155A4 (fr) | Polypeptides effecteurs crispr-cas et procédés d'utilisation associés | |
| MA56457A (fr) | Modulateurs de hsd17b13 et leurs procédés d'utilisation | |
| EP3810615A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| MA52797A (fr) | Inhibiteurs de masp -2 et procédés d'utilisation | |
| MA71645A (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP4034605A4 (fr) | Compositions de polissage et leurs procédés d'utilisation | |
| EP4284365A4 (fr) | Inhibiteurs de cdk2 et leurs procédés d'utilisation | |
| EP3941475A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3987021A4 (fr) | Lieurs protéiques optimisés et procédés d'utilisation | |
| EP3830128A4 (fr) | Anticorps anti-mica/b qui bloquent l'élimination de mica/b et procédés d'utilisation | |
| MA53328A (fr) | Anticorps anti-siglec-5 et leurs procédés d'utilisation |